Summary: I was bullish on Acadia back in November and its share price has climbed
Summary: Rett Syndrome is a rare genetic disorder affecting females that results in a slow
Summary: Today, we are circling back on mid-cap biopharma ACADIA Pharmaceuticals Inc. for the first
Summary: Acadia released its Q322 earnings this week. Revenues of $131m and a net loss
Summary: Once a proud pipeline in a molecule, NUPLAZID (pimavanserin) rests on its old standby
Summary: Aside from being launched for Parkinson’s, Nuplazid is potentially gaining two additional label expansions.
Summary: Acadia won approval for its only commercialized drug Nuplazid in 2017 and has tried
Summary: The lead drug (Nuplazid) is enjoying aggressive sales growth and thereby trumping competitors. In
Summary: Acadia reported solid earnings for Q3, 2021 despite COVID-19 headwind lashing its Parkinson’s Disease